INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud and unlawful business practices, with a deadline for investors to join the lawsuit by April 6, 2026 [1]. Company Developments - On July 9, 2025, Ultragenyx and Mereo BioPharma Group announced progress in the Phase 3 Orbit study for UX143 (setrusumab) in patients with osteogenesis imperfecta, with a final analysis expected by the end of the year [1]. - Following this announcement, Ultragenyx's stock price dropped by $10.41, or 25.11%, closing at $31.04 on July 10, 2025 [1]. - On December 29, 2025, Ultragenyx reported that its Phase III Orbit and Cosmic Studies did not achieve statistical significance in their primary endpoints, leading to a further stock price decline of $14.47, or 42.32%, closing at $34.19 [1]. Legal Context - The class action lawsuit is focused on whether Ultragenyx and its executives engaged in fraudulent activities that misled investors [1]. - Pomerantz LLP, the law firm handling the case, has a history of successful litigation in securities fraud and corporate misconduct cases [1].